# Valnoctamide-$d_5$

| | |
|---|---|
| **Cat. No.:** | HY-121877S |
| **CAS No.:** | 1190015-82-7 |
| **Molecular Formula:** | $C_8H_{12}D_5NO$ |
| **Molecular Weight:** | 148.26 |
| **Target:** | GABA Receptor; Isotope-Labeled Compounds |
| **Pathway:** | Membrane Transporter/Ion Channel; Neuronal Signaling; Others |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |




## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | Valnoctamide-$d_5$ is the deuterium labeled Valnoctamide. Valnoctamide (Valmethamide), a derivative of valproate, suppresses benzodiazepine-refractory status epilepticus. Valnoctamide (Valmethamide) acts directly on GABAA receptors[1][2]. |
| **In Vitro** | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

## REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Spampanato J, et al. Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus. Epilepsia. 2014 Sep;55(9):e94-8.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA